Men undergoing chemotherapy for cancer treatment are more likely to have worse heart muscle disease as compared to women, according to a research.
Cardiomyopathy is an acquired or hereditary disease of the heart muscle, charaterised by breathlessness, swollen legs and feet and a bloated stomach.
The results, presented at the EuroCMR 2017 in Prague, showed that both left and right ventricular ejection fraction was significantly lower in men than women, indicating worse performance of the heart.
Cardiac volumes and mass were significantly larger in men compared to women, indicating more damage to the heart's structure.
"The results of our study suggest that men developed a more severe form of chemotherapy-induced cardiomyopathy than women," said lead author Iwan Harries, from the University of Bristol, in Britain.
"Cancer patients are living longer because of improved treatment but the side effects of treatment include cardiovascular morbidity and mortality," Harries said.
Previous studies in paediatric populations which found increased risk in females may be explained by the absence of female sex hormones early in life. In adults it may be that female sex hormones are protective.
"Previous lab-based research has shown that female adult rat cardiac muscle cells have a survival advantage over male cells when challenged with oxidative stress-induced cell death, which is one of the proposed mechanisms of chemotherapy-induced cardiomyopathy," Harries explained.
For the study, the team included 76 patients (45 women and 31 men) and observed patients that received potentially cardiotoxic chemotherapy, and were referred for CMR scan, which provide information on left and right ventricular function, cardiac volumes, and tissue characteristics.
--IANS
rt/in/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
